287 related articles for article (PubMed ID: 9131805)
1. A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
de Diego JA; Penin P; Arribas JR; Vázquez E; Vázquez JJ
Folia Microbiol (Praha); 1996; 41(6):513-6. PubMed ID: 9131805
[TBL] [Abstract][Full Text] [Related]
2. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
3. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Podzamczer D; Miró JM; Ferrer E; Gatell JM; Ramón JM; Ribera E; Sirera G; Cruceta A; Knobel H; Domingo P; Polo R; Leyes M; Cosin J; Fariñas MC; Arrizabalaga J; Martínez-Lacasa J; Gudiol F
Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):89-95. PubMed ID: 10746493
[TBL] [Abstract][Full Text] [Related]
4. Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Sina S; Mohammad JM; Reza S; Anita M; Soudabeh E; Hadi M
Eur J Med Res; 2021 Jun; 26(1):65. PubMed ID: 34193287
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients.
Kongsaengdao S; Samintarapanya K; Oranratnachai K; Prapakarn W; Apichartpiyakul C
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(1):11-6. PubMed ID: 17517949
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
8. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Jost C; Reiter-Owona I; Liesenfeld O
Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
[TBL] [Abstract][Full Text] [Related]
9. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.
Derouin F; Almadany R; Chau F; Rouveix B; Pocidalo JJ
Antimicrob Agents Chemother; 1992 May; 36(5):997-1001. PubMed ID: 1324642
[TBL] [Abstract][Full Text] [Related]
11. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
12. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Mahmoud MS
J Egypt Soc Parasitol; 1999; 29(3):791-803. PubMed ID: 12561919
[TBL] [Abstract][Full Text] [Related]
13. A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections.
Li Y; Zeng YM; Lu YQ; Qin YY; Chen YK
Medicine (Baltimore); 2020 May; 99(20):e20146. PubMed ID: 32443329
[TBL] [Abstract][Full Text] [Related]
14. Determination of the inhibitory effect on Toxoplasma growth in the serum of AIDS patients during acute therapy for toxoplasmic encephalitis.
Derouin F; Gérard L; Farinotti R; Maslo C; Leport C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):50-4. PubMed ID: 9732069
[TBL] [Abstract][Full Text] [Related]
15. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
[TBL] [Abstract][Full Text] [Related]
16. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.
Barbosa BF; Gomes AO; Ferro EA; Napolitano DR; Mineo JR; Silva NM
Vet Parasitol; 2012 Jun; 187(1-2):44-52. PubMed ID: 22281151
[TBL] [Abstract][Full Text] [Related]
17. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Podzamczer D; Miró JM; Bolao F; Gatell JM; Cosín J; Sirera G; Domingo P; Laguna F; Santamaría J; Verdejo J
Ann Intern Med; 1995 Aug; 123(3):175-80. PubMed ID: 7598298
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the efficacy of azithromycin and pyrimethamine, for treatment of experimental infection of mice with Toxoplasma gondii cystogenic strain].
Lescano SA; Amato Neto V; Chieffi PP; Bezerra RC; Gakiya E; Ferreira CS; Braz LM
Rev Soc Bras Med Trop; 2004; 37(6):460-2. PubMed ID: 15765594
[TBL] [Abstract][Full Text] [Related]
19. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome.
Van Delden C; Hirschel B
J Infect Dis; 1996 May; 173(5):1294-5. PubMed ID: 8627092
[No Abstract] [Full Text] [Related]
20. Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis.
Shiojiri D; Kinai E; Teruya K; Kikuchi Y; Oka S
Emerg Infect Dis; 2019 Apr; 25(4):841-843. PubMed ID: 30882331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
